Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam.
calcitonin gene‐related peptide
drug–drug interactions
migraine
pharmacokinetics
phase‐I clinical study
rimegepant
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
revised:
30
07
2024
received:
23
01
2024
accepted:
31
07
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
aheadofprint
Résumé
Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining the in vivo potential of rimegepant (75 mg) for cytochrome P450 (CYP) 3A4-related drug-drug interactions (DDIs). Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene-related peptide receptor antagonist approved for acute treatment of migraine and preventive treatment of episodic migraine. People with migraine commonly use multiple drug treatments, with the potential for DDIs. Each study was an open-label, single-arm, single-sequence, crossover study. Rimegepant was tested as a victim drug by separate co-administration of itraconazole (a strong CYP3A4 inhibitor and P-glycoprotein inhibitor) in Study 1, rifampin (a strong CYP3A4 inducer and moderate CYP2C9 inducer) in Study 2, and fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) in Study 3, and as a perpetrator drug by co-administration with midazolam (a CYP3A4 substrate) in Study 4. Mean values of single-dose rimegepant maximum concentration (C Based on the magnitude of DDIs, these studies indicate the following: co-administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co-administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co-administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.
Sections du résumé
OBJECTIVE
OBJECTIVE
Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining the in vivo potential of rimegepant (75 mg) for cytochrome P450 (CYP) 3A4-related drug-drug interactions (DDIs).
BACKGROUND
BACKGROUND
Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene-related peptide receptor antagonist approved for acute treatment of migraine and preventive treatment of episodic migraine. People with migraine commonly use multiple drug treatments, with the potential for DDIs.
METHODS
METHODS
Each study was an open-label, single-arm, single-sequence, crossover study. Rimegepant was tested as a victim drug by separate co-administration of itraconazole (a strong CYP3A4 inhibitor and P-glycoprotein inhibitor) in Study 1, rifampin (a strong CYP3A4 inducer and moderate CYP2C9 inducer) in Study 2, and fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) in Study 3, and as a perpetrator drug by co-administration with midazolam (a CYP3A4 substrate) in Study 4.
RESULTS
RESULTS
Mean values of single-dose rimegepant maximum concentration (C
CONCLUSIONS
CONCLUSIONS
Based on the magnitude of DDIs, these studies indicate the following: co-administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co-administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co-administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : This study was sponsored by Biohaven, which was acquired by Pfizer in October 2022
Informations de copyright
© 2024 Pfizer, Inc and The Author(s). Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
Références
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1‐211.
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021‐1039.
Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973‐989.
Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: From drug‐drug interactions to personalized medicine. J Headache Pain. 2019;20:56.
PubChem. National Library of Medicine (US), National Center for Biotechnology Information: PubChem Compound Summary for CID 51049968, Rimegepant; 2004. Accessed May 23, 2024. https://pubchem.ncbi.nlm.nih.gov/compound/Rimegepant
Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP pathway for acute and preventive treatment of migraine: The evolution of success. J Med Chem. 2020;63:6600‐6623.
Lipton RB, Conway CM, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: Results from a double‐blind, randomized, placebo‐controlled trial, study 301. Headache. 2018;58:1136‐1137.
Croop R, Berman G, Kudrow D, et al. Long‐term safety of rimegepant 75 mg for the acute treatment of migraine (study 201) (4829). Neurology. 2020;94:4829.
Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double‐blind, placebo‐controlled trial. Lancet. 2019;394:737‐745.
Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: A phase 2/3, randomised, double‐blind, placebo‐controlled trial. Lancet. 2021;397:51‐60.
Yu S, Kim BK, Guo A, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: A phase 3, double‐blind, randomised, placebo‐controlled trial. Lancet Neurol. 2023;22:476‐484.
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS‐927711 for the acute treatment of migraine: A double‐blind, randomized, placebo controlled, dose‐ranging trial. Cephalalgia. 2014;34:114‐125.
Li Y, Wang X, Ballesteros‐Perez A, Bertz R, Lu Z. Pharmacokinetics and safety of single and multiple daily dosing of 75‐mg rimegepant orally disintegrating tablets in healthy Chinese adults: A randomized placebo‐controlled trial. Clin Pharmacol Drug Dev. 2023;12:594‐601.
Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene‐related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142‐149.
FDA. Rimegepant Prescribing Information; 2021. Accessed May 23, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf
FDA. Rimegepant NDA 212728orig1s000 Integrated Clinical Pharmacology Review; 2020. Accessed May 24, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000ClinPharmR.pdf
Rendic S, Guengerich FP. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol. 2015;28:38‐42.
Bhardwaj R, Collins JL, Stringfellow J, et al. P‐glycoprotein and breast cancer resistance protein transporter inhibition by cyclosporine and quinidine on the pharmacokinetics of oral rimegepant in healthy subjects. Clin Pharmacol Drug Dev. 2022;11:889‐897.
Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan suicidality tracking scale (Sheehan‐STS): Preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6:26‐31.
Sheehan DV, Giddens JM, Sheehan IS. Status update on the Sheehan‐Suicidality Tracking Scale (S‐STS) 2014. Innov Clin Neurosci. 2014;11:93‐140.
Posner K, Brown GK, Stanley B, et al. The Columbia‐Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266‐1277.
FDA. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers; 2023. Accessed May 24, 2024. https://www.fda.gov/drugs/drug‐interactions‐labeling/drug‐development‐and‐drug‐interactions‐table‐substrates‐inhibitors‐and‐inducers
Croop R, Ivans A, Stock DA, et al. A phase 1 study to evaluate the bioequivalence of oral table and orally dissolving tablet formulations of rimegepant, a small molecule CGRP receptor antagonist. Cephalalgia. 2018;38:142‐143.
FDA. Clinical Drug Interaction Studies—Cytochrome P450 Enzyme‐ and Transporter‐Mediated Drug Interactions Guidance for Industry. 2020 Accessed May 24, 2024. https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/clinical‐drug‐interaction‐studies‐cytochrome‐p450‐enzyme‐and‐transporter‐mediated‐drug‐interactions
EMA. Guideline on the Investigation of Drug Interactions. 2012 Accessed May 23, 2024. https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐drug‐interactions‐revision‐1_en.pdf
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys. Headache. 2021;61:60‐68.
Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23:34.